

Electronic supplementary material

ESM Table 1 Clinical characteristics of the analysis population

| | GOAL A1C study (<i>n</i> =5,549) | GOT study (<i>n</i> =4,417) | Combined analysis population (<i>n</i> =9,966) |
|---|--------------------------------------|---------------------------------|--|
| Sex (% female) | 48.9 | 51.4 | 50.0 |
| Age (years) | 56.9±11.5 | 55.9±11.4 | 56.4±11.5 |
| BMI (kg/m ²) | 34.4±7.8 | 34.8±7.6 | 34.5±7.7 |
| Duration of diabetes (years) | 8.6±6.4 | 8.3±6.3 | 8.5±6.4 |
| Baseline HbA _{1c} (%) | 8.9±1.5 | 9.2±1.6 | 9.0±1.6 |
| Week 12 HbA _{1c} (%) | 7.7±1.0 | 7.7±1.1 | 7.7±1.1 |
| Endpoint HbA _{1c} (%) | 7.4±1.0 | 7.4±1.0 | 7.4±1.0 |
| Baseline fasting blood glucose (mmol/l) | 10.0±3.0 | 9.9±3.1 | 9.9±3.1 |
| Week 12 fasting blood glucose (mmol/l) | 6.4±1.9 | 5.9±2.2 | 6.2±2.1 |
| Endpoint fasting blood glucose (mmol/l) | 5.9±1.8 | 5.6±2.1 | 5.8±1.9 |
| Endpoint daily insulin dose (U) | 53.5±35.7 | 71.4±40.4 | 61.1±38.9 |

Data are mean±SD